If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
=== Simulated chemical pathways === In 2020, chemists described possible chemical pathways from nonliving prebiotic chemicals to complex biochemicals that could give rise to living organisms, based on a new computer program named AllChemy.
This cylindrical representation of the incompressible Navier–Stokes equations is the second most commonly seen (the first being Cartesian above). Cylindrical coordinates are chosen to take advantage of symmetry, so that a velocity component can disappear. A very common case is axisymmetric flow with the assumption of no tangential velocity (
== The LAL test == There are three basic methodologies: gel-clot, turbidimetric, and chromogenic. The primary application for LAL is the testing of parenteral pharmaceuticals and medical devices that contact blood or cerebrospinal fluid. In the United States, the FDA has published a guideline for validation of the LAL test as an endotoxin test for such products. The LAL cascade is also triggered by (1,3)-β-D-glucan, via a different Factor G. Both bacterial endotoxins and (1,3)-β-D-glucan are considered pathogen-associated molecular patterns, or PAMPs, substances which elicit inflammatory responses in mammals.
=== Available forms === Dutasteride was originally provided in the form of soft, oil-filled gelatin capsules containing 0.5mg dutasteride each. In India, manufacturers variously formulate tablets and soft and hard capsules of 0.5mg while many versions come combined with tamsulosin, alfuzosin or silodosin. A 0.1mg capsule is also available in Japan.
== Gene == The human CUX1 gene is large, encompassing more than 440,000 base pairs with two alternative first exons and an additional 23 exons. The last exon has a weak polyadenylation site allowing RNA polymerase II often to continue transcribing until it reaches an additional 10 exons. Splicing of this longer transcript from exon 14 to exon 25 generates a mature mRNA that codes for a protein that was called CASP (Cut alternatively spliced product). CASP localizes to the Golgi and does not seem to impact at all on CUX1 function. However, because of the complex structure of the gene, most oligos in microarrays were derived from the most 3' exons that are unique to CASP. Thus, until the advent of RNA sequencing CUX1 expression data has been essentially limited to immunohistochemical analyses. Similarly, many guide RNAs in CRISPR-Cas screening studies target the CASP-specific exons and do not affect CUX1.
Sources: en.wikipedia.org
chemical species Also simply called a chemical. A chemical substance or ensemble of substances composed of chemically identical molecular entities which can explore the same set of molecular energy levels on a characteristic or delineated time scale.
==== Associate of the Royal Red Cross (ARRC) ==== Staff Sergeant Natalie Dawn Davies, Queen Alexandra's Royal Army Nursing Corps, Q1048809. Major Adam Gordon Hughes, Queen Alexandra's Royal Army Nursing Corps, 30081582. Major Jennifer Elizabeth Jackson, , Queen Alexandra's Royal Army Nursing Corps, Army Reserve, 518454.
In September 2010, Labcorp acquired Genzyme Genetics, formerly a division of Genzyme Corporation, with 9 testing laboratories and approximately 1,900 employees, for $925 million in cash. In February 2011, Labcorp acquired the assets of bankrupt Westcliff Medical Laboratory. The FTC challenged the acquisition but lost in court. In June 2011, Labcorp acquired Canadian central labs partner Clearstone from Czura Thornton, adding laboratories in China, France, Singapore and Canada, and the central laboratory protocol management system APOLLO CLPM. In November 2011, Labcorp acquired more than 90% of the shares of DNA testing company Orchid Cellmark for $85 million. To receive approval of the transaction from the Federal Trade Commission, Labcorp sold parts of Orchid's DNA paternity testing business to DNA Diagnostics Center. In May 2012, Labcorp Clinical Trials sold its European biological sampling kit building operation located in Hamburg to Marken. In August 2012, Labcorp acquired testing lab Medtox Scientific for $241 million. In September 2013, Labcorp acquired MuirLab, the clinical laboratory outreach business of John Muir Health. In November 2014, Labcorp acquired LipoScience, a developer of diagnostic tests based on nuclear magnetic resonance spectroscopy measuring heart disease risk, for $85 million. In December 2014, Labcorp acquired Bode Technology Group, a provider of forensic DNA analysis, DNA collection products, and relationship testing and the largest DNA forensic testing company in the U.S., from SolutionPoint International.
PKS, carbon-carbon bond formation through Claisen condensation reaction NRPs, the C domain catalyzes the amide bond formation between the amino acid it adds to the chain (on the PCP of one module) and the nascent peptide (on the PCP of the next module).
Sources: en.wikipedia.org
As a genetic disorder, the mainstay of twenty-first-century prevention of osteogenesis imperfecta is based on preventing affected individuals from being born in the first place. Genetic counseling can help patients and their families determine what types of screening, if any, are right for their situation. Patients can consider preimplantation genetic diagnosis after in vitro fertilization to select fertilized embryos that are not affected. Common mutations which cause OI may be caught by exome sequencing and whole genome sequencing. If a pregnancy is already in progress, the procedure of amniocentesis may be undergone to see if the fetus is affected. If affected, it is up to the family to consider whether or not they want to terminate the pregnancy and try again—raising questions of medical ethics and a woman's right to choose. Without intervention, patients with the most common mutations causing osteogenesis imperfecta have a 50% chance per gestation of passing on the disorder, as these mutations are inherited in an autosomal dominant pattern of Mendelian inheritance. Those with the rare autosomal recessive forms of OI have a 25% chance of passing on the disorder. Genetic testing of the affected members of the family can be used to determine which inheritance pattern applies. As OI type I may be difficult to detect in a newborn child, the cord blood of the child can be tested to determine if it has been passed on, if the family has already rejected the more invasive genetic screening methods.
== External links == Video: Hide & Animal Protein Glue: How to Select, Make & Use Video on hide glue, by Keith Cruickshank Old Brown Glue - Articles Why Not Period Glue? - article by W. Patrick Edwards on hide glue WPatrickEdwards: Why Use Reversible Glue?
For a given total heat output, reducing waste volume increases heat density; the space required in a repository also depends on the host rock and its temperature limits. Radioactivity is not the same as the dose potentially received from a waste repository. A 2023 DOE assessment noted that waste radiotoxicity is strongly linked to actinide content, while mobile, long-lived fission and activation products can be important contributors to repository dose. Under typical repository conditions, actinides move more slowly than these products. In principle, breeder fuel cycles can recycle and consume all actinides, leaving only fission products. The table illustrates the gap between medium-lived and long-lived fission products. A 2015 measurement put the half-life of samarium-151, one of the medium-lived fission products, at 94.6±0.6 years. As a result of this physical oddity, after several hundred years in storage, the activity of the radioactive waste from an FBR would quickly drop to the low level of the long-lived fission products. However, to obtain this benefit requires the highly efficient separation of transuranics from spent fuel. If the fuel reprocessing methods used leave a large fraction of the transuranics in the final waste stream, this advantage would be greatly reduced. The FBR's fast neutrons can fission actinide nuclei with even numbers of both protons and neutrons. Such nuclei usually lack the low-speed "thermal neutron" resonances of fissile fuels used in LWRs. The thorium fuel cycle inherently produces lower levels of heavy actinides.
== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.
== Sources == Watkins, Elizabeth Siegel (2009). "From History of Pharmacy to Pharmaceutical History". Pharmacy in History. 51 (1): 3–13. PMID 20027914. (in Japanese) Asai, T. (1985). Nyokan Tūkai. Tokyo: Kōdan-Sha. (in French) Titsingh, Isaac, ed. (1834). [Siyun-sai Rin-siyo/Hayashi Gahō, 1652], Nipon o daï itsi ran; ou, Annales des empereurs du Japon. Paris: Oriental Translation Fund of Great Britain and Ireland....Click link for digitized, full-text copy of this book (in French) Pharmacy Consulting Services | McKesson Archived 14 December 2019 at the Wayback Machine – A landmark study in hospital pharmacy performance based on an extensive literature review and the collective experience of the Health Systems Pharmacy Executive Alliance.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.